H
Hcs Pharma
A company specializing in cell imaging
About Hcs Pharma
HCS Pharma is a French biotechnology company specializing in the development of advanced 3D cellular assays. These assays utilize natural hyaluronic acid-based hydroscaffolds to better mimic tissue microenvironments, providing more predictive tools for drug development. The company primarily serves pharmaceutical and biotech firms looking to enhance their drug discovery processes. Operating in the global biotechnology market, HCS Pharma employs a business model that includes custom assay development and product sales. Revenue is generated through the sale of these specialized assays and related services. Recently, the company has been involved in innovative fundraising efforts, including a EUR 7.3 million raise through a security token offering (STO). This approach highlights their commitment to leveraging cutting-edge financial technologies to support their growth.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Loos, France
- Employees
- 3
- Open positions
- None listed
- Dealroom signal
- 60.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Woman Founder, Horizon Europe
- Technology
- 3D Technology, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AEquity / VC | Mar 2022 | $2.2M | $8.8M | Undisclosed | — |
| LATE VC✓Equity / VC | Aug 2021 | $22M | $88M | Global Emerging Markets | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Hcs Pharma is 4.1K monthly website visits, down 70.7% over the last three months. Hcs Pharma's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Global Emerging Markets
Other known investors6 additional known investors
CNRS Innovation
Eurasanté
French National Centre for Scientific Research - CNRS
Ouest Valorisation
Finovam
Nord France Amorcage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hcs Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hcs Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.